$11.47 0.0 0.0%
Last Trade - 15/01/21
Market Cap | £291.6m |
Enterprise Value | £816.0m |
Revenue | £599.2m |
Position in Universe | 3500th / 6547 |
Industry | Market | |
---|---|---|
|
|
|
|
|
|
|
|
Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
---|---|---|---|---|---|---|---|---|---|---|
560.7 | 653 | 766.8 | 729 | 805.8 | 822.5 | 817.6 | 835.3 | +8.0% | ||
+911.3 | +16.3 | -75.9 | ||||||||
x
|
||||||||||
Profitability | ||||||||||
%
|
||||||||||
%
|
||||||||||
%
|
||||||||||
Cashflow | ||||||||||
Dividends | ||||||||||
Balance Sheet | ||||||||||
m
|
||||||||||
m
|
||||||||||
m
|
||||||||||
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing % | |||
Net Gearing % | |||
Cash / Assets % |
Liquidity (ttm) | ||
---|---|---|
Curr. Ratio | ||
Quick Ratio | ||
Interest Cov. |
Efficiency (ttm) | ||
---|---|---|
Asset Turnover | ||
Recs Turnover | ||
Stock Turnover |
Latest interim period vs. prior period | Industry | Market |
---|---|---|
|
|
|
|
|
3yr Compound Annual Growth Rate | Industry | Market |
---|---|---|
|
|
|
|
|
|
|
|
American Renal Associates Holdings, Inc. is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia. The Company operates its dialysis clinics exclusively through a JV model, in which it partners primarily with local nephrologists to develop, own and operate dialysis clinics, while the providers of the majority of dialysis services in the United States operate through a combination of subsidiaries and joint ventures. It provides patient care and clinical outcomes to patients suffering from end-stage renal disease (ESRD). Its clinics offer both in center and home dialysis options to meet the needs of patients. Its clinics primarily provide in center hemodialysis treatments and ancillary items and services.
Last Annual | December 31st, 2019 |
Last Interim | September 30th, 2020 |
Incorporated | March 18, 2010 |
Public Since | April 21, 2016 |
No. of Shareholders: | 217 |
No. of Employees: | 4,977 |
Sector | Healthcare |
Industry | Healthcare Providers & Services |
Index | |
Exchange | New York Stock Exchange |
Shares in Issue | 34,543,295 |
Free Float | (0.0%) |
Eligible for |
ISAs
SIPPs
|
Address | American Renal Holdings,Inc 500 Cummings Center Suite 6550, BEVERLY, 01915, United States |
Web | http://ir.americanrenal.com/ |
Phone | +1 978 9223080 |
Contact | Darren Lehrich (SVP Strategy & Investor Relations) |
Auditors | Grant Thornton LLP |
As of 15/01/21, shares in American Renal Associates Holdings Inc are trading at $11.47, giving the company a market capitalisation of £291.6m. This share price information is delayed by 15 minutes.
Shares in American Renal Associates Holdings Inc are currently trading at $11.47 and the price has moved by 16.57% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the American Renal Associates Holdings Inc price has moved by 2.26% over the past year.
Of the analysts with advisory recommendations for American Renal Associates Holdings Inc, there are there are currently 0 "buy" , 3 "hold" and 0 "sell" recommendations. The overall consensus recommendation for American Renal Associates Holdings Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.
American Renal Associates Holdings Inc is scheduled to issue upcoming financial results on the following dates:
American Renal Associates Holdings Inc does not currently pay a dividend.
American Renal Associates Holdings Inc does not currently pay a dividend.
American Renal Associates Holdings Inc does not currently pay a dividend.
To buy shares in American Renal Associates Holdings Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in American Renal Associates Holdings Inc are currently trading at $11.47, giving the company a market capitalisation of £291.6m.
Here are the trading details for American Renal Associates Holdings Inc:
Based on an overall assessment of its quality, value and momentum, American Renal Associates Holdings Inc is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in American Renal Associates Holdings Inc are currently priced at $11.47. At that level they are trading at 12.82% premium to the analyst consensus target price of 0.00.
Analysts covering American Renal Associates Holdings Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.16 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like American Renal Associates Holdings Inc. Over the past six months, the relative strength of its shares against the market has been 43.67%. At the current price of $11.47, shares in American Renal Associates Holdings Inc are trading at 37.83% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for American Renal Associates Holdings Inc.
American Renal Associates Holdings Inc's management team is headed by:
Here are the top five shareholders of American Renal Associates Holdings Inc based on the size of their shareholding: